about
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cellsCD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases.Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy.Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes.The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3).Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaAntibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections.Monoclonal antibodies in the immunotherapy of autoimmune diseases.Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin.Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.CD20: a target antigen for immunotherapy of autoimmune diseases.Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease.Antiphospholipids Syndrome Complicated by a Systemic Capillary Leak-Like Syndrome Treated With Steroids and Intravenous Immunoglobulins: A Case Report.Cloning and chromosomal localization of a cDNA encoding a mitochondrial porin from Drosophila melanogaster.New therapies in multiple myeloma.Rheumatic disorders as paraneoplastic syndromes.Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.Autoantibodies to intracellular antigens: generation and pathogenetic role.Extra-articular manifestations of rheumatoid arthritis: An update.Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature.Raynaud's phenomenon: from molecular pathogenesis to therapy.Vasculitides: Proposal for an integrated nomenclature.International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosEvaluation of biotinylated cells as a source of antigens for characterization of their molecular profile.Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases.Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody.Syngeneic anti-idiotypic antisera to murine monoclonal antibodies to monomorphic and polymorphic determinants of HLA class I antigens.Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma.Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies.Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders.Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort.Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis
P50
Q26866479-5B6F3E50-7530-40D5-A942-16A93E538E72Q30388433-2CA44F44-C25E-41D6-9DA8-B744400F6E9FQ31152009-8DBF7214-049D-45E6-9FF7-987992051431Q33222428-B8CCB296-6BDE-432F-B4C3-95DB20E6B06BQ33225137-2C388AE1-F24A-49E2-A169-C1D536584FD2Q33306329-FC9F3E43-560D-4360-9925-0F03EC1459A3Q33395923-46569D1C-855F-473B-89A9-3BC1E0A6E4CAQ33632892-08CE5C4C-CBD6-491B-BDEE-F1FC19D42E2FQ33677445-9E960DF8-B6FF-408A-ADF0-16BF8F04818DQ34043387-71CBB932-DB85-4B50-BD44-202480745587Q34499858-9278BEC6-E30C-494B-9A43-2724DE6FA480Q34684413-C20B9A5F-3227-410B-B259-E60D15F1B704Q35802808-0274E4EA-1ED9-40C4-9366-D71026620B25Q36060142-19DDE96D-1B1F-42A8-B932-1C02C5B52A57Q36281233-D13A255D-9384-4842-B05E-D026F01B0CC0Q36346063-761B67EA-BB12-4902-848D-42D11951967DQ36566894-7E9B3E48-F2BC-45CB-A2D7-2C15CCBE832BQ36818656-45492584-A2F1-4F1B-9C7F-F71636B39F3FQ36986576-B9028B3D-BFC4-4AFA-86DB-D15CC1EDBD10Q37166826-00298035-DD70-43BF-99B8-BB039787E8D8Q37690559-EDDE129F-A93B-46C5-8DA3-AC2C567C2863Q37702412-3AA01B4B-878D-465E-A727-282F7B4E2012Q37852410-EE4292CA-AD79-4DED-9BE6-A2E66CD5FB30Q37937133-515D1232-22ED-4E85-9890-731DF136B9E1Q38172332-9287FC87-EEA9-4BE0-AD2E-8844F65EA1B5Q38177961-CE8AF8A3-D8C0-4A49-81F9-3F48E3F89B10Q38627544-14026E96-9E18-427E-8D32-A10CB4E07683Q38657993-0B61E3A6-B11A-4966-8BBB-C9D455F13659Q40983107-2FFF657A-826E-4B66-B501-6E408716ACEAQ41108942-6232F031-A7B9-492B-A4A0-1AACB1C9EDB9Q41510495-970DA6F5-4B6E-456A-95C4-5A3938EE3D29Q41705185-8C26FACE-BC37-49B6-853A-4295698AED67Q43518451-A92D642B-73D3-4691-959B-502C7604A362Q46256954-AFF6F072-00FA-495D-AAE9-B5FA17A59EDBQ47110507-603FAF2A-5753-4F75-AD71-CD37C498AF81Q47174379-FCE1C8EF-0D95-40DE-AA8E-345B93BCD0BBQ47192693-826065CF-C27D-4995-A562-D03B3D1AF7A7Q48503936-BB179308-D69F-4A81-9C70-FDCB90C13A30Q52587397-37393807-F56B-4EA8-83AA-8F1CA2A5D763Q58609356-61C8A219-BF73-4E4E-9884-4F369CAAF89E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federico Perosa
@ast
Federico Perosa
@en
Federico Perosa
@es
Federico Perosa
@nl
Federico Perosa
@sl
type
label
Federico Perosa
@ast
Federico Perosa
@en
Federico Perosa
@es
Federico Perosa
@nl
Federico Perosa
@sl
prefLabel
Federico Perosa
@ast
Federico Perosa
@en
Federico Perosa
@es
Federico Perosa
@nl
Federico Perosa
@sl
P106
P1153
6701663642
P21
P31
P496
0000-0002-4072-4244